JPML Asked to Create Federal Docket for Oral Decongestant Cases

  • Motion

WASHINGTON, D.C. — The Judicial Panel on Multidistrict Litigation has been asked to create a federal docket for lawsuits alleging that makers of over-the-counter oral decongestants knew the drugs’ active ingredient, pseudoephedrine, is essentially a placebo, yet marketed them as effective.

In a Sept. 18 motion, plaintiffs in one of the class actions pending in the U.S. District Court for the District of New Jersey argue that all of the pending actions - 13 so far – allege substantially the same wrongful conduct on the part of the named defendants, which include Procter & Gamble, McNeil Consumer Healthcare, GlaxoSmithKline LLC …


HarrisMartin's Webinar Series: Suboxone (Buprenorphine/Naloxone) Film Marketing, Sales Practices and Products Litigation - MDL No. 3092

December 18, 2023


HarrisMartin's New Jersey Asbestos Litigation Conference

March 01, 2024 - New Brunswick, NJ
Hyatt Regency New Brunswick